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Major depressive disorder (MDD) is a substantial burden to patients,
families, and society, but many patients cannot be treated adequately.
Rodent experiments suggest that the neuropeptide galanin (GAL) and
its three G protein-coupled receptors, GAL1–3, are involved in mood
regulation. To explore the translational potential of these results, we
assessed the transcript levels (by quantitative PCR), DNA methyl-
ation status (by bisulfite pyrosequencing), and GAL peptide by RIA of
the GAL system in postmortem brains fromdepressed personswho had
committed suicide and controls. Transcripts for all four members were
detected and showed marked regional variations, GAL and galanin re-
ceptor 1 (GALR1) being most abundant. Striking increases in GAL and
GALR3mRNA levels, especially in the noradrenergic locus coeruleus and
the dorsal raphe nucleus, in parallel with decreased DNA methylation,
were found in both male and female suicide subjects as compared with
controls. In contrast, GAL and GALR3 transcript levels were decreased,
GALR1 was increased, and DNA methylation was increased in the dor-
solateral prefrontal cortex of male suicide subjects, however, there
were no changes in the anterior cingulate cortex. Thus, GAL and its
receptorGALR3 are differentially methylated and expressed in brains of
MDD subjects in a region- and sex-specific manner. Such an epigenetic
modification in GALR3, a hyperpolarizing receptor, might contribute to
the dysregulation of noradrenergic and serotonergic neurons impli-
cated in the pathogenesis of MDD. Thus, one may speculate that
a GAL3 antagonist could have antidepressant properties by disinhibiting
the firing of these neurons, resulting in increased release of noradren-
aline and serotonin in forebrain areas involved in mood regulation.
epigenetics | human postmortem brain | neuropeptides | stress |
transmitter coexistence
Major depressive disorder (MDD) is a serious mental illnessaffecting up to 20% of the population at some point during
their lives, women more frequently than men, and representing a
major burden to patients, their families, and society (1, 2). MDD is
thought to arise from the interaction of genetic and environmental
factors, with stressful life events representing an important predis-
posing factor (3–5). Growing evidence suggests that epigenetic
mechanisms mediate such interactions, namely through altered DNA
methylation, thus leading to stable changes in brain function that may
underlie psychopathology (6, 7).
Pharmacological management of depression currently involves
drugs that often target the monoamine transporters, which include
selective reuptake inhibitors for serotonin (5-hydroxytryptamine,
5-HT) (SSRIs), noradrenaline (NA) inhibitors (NRIs), or a com-
bination of both (SNRIs) (8–10), as well as a number of other
medications (11). However, the therapeutic efficacy of these anti-
depressants is hampered by a slow onset of action, a limited re-
sponse rate, and considerable side effects (12, 13). These issues have
led to intensive search for novel therapeutic approaches for MDD
(14), including targeting receptors for neuropeptides (15–19), the
most diverse family of brain messenger molecules (20).
In this context, the 29/30 amino acid neuropeptide galanin
(GAL) (21), which is widely distributed in the rat (22–25) and
human (26) brain, may be of special interest. In particular, it co-
exists with NA in the locus coeruleus in both rat (27–29) and
human (26, 30–32) and in rat with 5-HT in the dorsal raphe nu-
cleus (28, 33, 34).
Significance
Depression is a seriously disabling disorder, twice as common in
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disorder, making it a possible drug target for this disease.
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GAL exerts its physiological actions via three subtypes of G
protein-coupled receptors, GAL1–3 (35, 36). The distribution of
these receptors has been mapped previously with ligand-binding
autoradiography in rat (37, 38), monkey, and human (39–41)
brain. More recently the receptor transcripts have been localized
with in situ hybridization in rat brain (42–44) and in some regions
of the human brain (32). It should be noted that GAL receptor
subtypes can form dimers and heterodimers, a mechanism that
can profoundly change GAL signaling (45).
Interestingly, certain differences between species exist in regions
of potential importance for mood-related disorders. For example,
galanin receptor 3 (GalR3) mRNA has a limited distribution in the
rat brain (44), where it could not even be detected in the first
publication on the cloning of this receptor (46). However, it appears
to be expressed in human noradrenergic locus coeruleus (NA-locus
coeruleus) neurons (32). In addition GAL itself has a different
profile: it is expressed in 5-HT neurons in the dorsal raphe nucleus
in the rat but not in humans, but its expression in the locus
coeruleus is conserved in the species investigated to date.
Animal studies have provided strong evidence that the GAL
system is involved in anxiety- and depression-like behavior (33, 47–
55). A recent genetic association study supports a possible role of the
GAL system in mood disorders, pointing to involvement of epige-
netic processes and a strong association with high levels of stress
(56). Moreover, there is an interaction between GAL and the
5-HT1A receptor (47), a receptor that plays an important role as
autoreceptor in depression, as shown in experimental studies (57, 58)
and in studies of suicide victims (59). In agreement with many ani-
mal experimental studies, PET imaging also has indicated a role
for postsynaptic 5-HT1A receptors in depression (60).
The aim of the present study was to identify possible changes in
the GAL system in MDD by analyzing postmortem brains from
depressed subjects who committed suicide (hereafter “DS” subjects)
and matched subjects without psychiatric symptoms (hereafter,
simply “controls”). We used quantitative PCR (qPCR) to monitor
transcript levels, bisulfite pyrosequencing to study DNA methyl-
ation (GAL and GALR1-3), and RIA to establish GAL peptide
levels. All three analyses were carried out on the same samples from
five different, relevant brain regions: dorsolateral prefrontal cortex
[Brodmann area (BA) 8/9], anterior cingulate cortex (BA 24), locus
coeruleus, dorsal raphe nucleus, and the medullary raphe nuclei.
Results
Cohort Demographics. There were no significant differences be-
tween DS subjects and their matched controls in age (DS subjects
vs. controls: 51.6 ± 15.4 vs. 57.5 ± 15.4 y, P = 0.11); postmortem
interval (PMI) (DS subjects vs. controls: 43.56 ± 24.16 vs. 49.21 ±
34.44 h, P = 0.94); brain pH (DS subjects vs. controls: 6.61 ±
0.29 vs. 6.46 ± 0.34; P = 0.13); or RNA integrity number (RIN)
(DS subjects vs. controls: 6.49 ± 1.70 vs. 6.68 ± 1.62; P < 0.49).
The details of the demographic characteristics of DS subjects and
controls for each of the regions analyzed are provided in Table 1,
and detailed information on each individual subject is provided
in Table S1.
Sample Anatomy. The five brain regions analyzed encompass a
heterogeneous collection of neurons. It is important to note that in
the samples labeled locus coeruleus and especially in those labeled
dorsal raphe and medullary raphe only a part of these neurons are
monoaminergic (SI Materials and Methods, Brain Samples).
The Effects of Medication.An inherent problem of autopsy analysis
is the effect of medication, particularly when looking at a dynamic
parameter, such as transcripts. For example, it has been reported
that an antidepressant can exert epigenetic changes (61, 62). We
have analyzed the data using ANOVA followed by Fisher’s least
significant difference post hoc test and ANCOVA by treating an-
tidepressants as a confounding factor to compare the effects in
male and female DS subjects. The samples were divided into four
groups based on the different medications, namely (i) SSRIs,
(ii) SSRI + benzodiazepines, (iii) SSRI + others (including SNRIs,
serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine-
dopamine reuptake inhibitors, tricyclic antidepressants, and
noradrenergic and specific serotonergic antidepressants; details
are given in Table S1), and (iv) none. Based on the analysis, we
conclude that in our study the various psychiatric medications
show no significant effect on the gene expression of GAL and
GalR3 in the five regions analyzed. The longer imprints of DNA
methylation would require analysis of the complete anamnesis.
Transcript Levels Vary Across Brain Regions. The overall distribution
and levels of the transcripts of the galanin system are summarized in
Table 2. Briefly, transcripts for GAL and GAL1–3 are differentially
expressed in the five brain regions, with the difference reaching
statistical significance for all the markers studied (see Tables S2 and
S3 for P values). GAL is expressed at high levels in the lower
brainstem and at three- to-fourfold lower levels in the two cortical
Table 1. Demographic characteristics of the cohort
Samples DLPFC ACC DRN LC MRN
Size 40 40 42 42 47
% male controls (n) 25 (10) 25 (10) 26.1 (11) 23.8 (10) 25.5 (12)
% male DS subjects (n) 25 (10) 25 (10) 24.1 (10) 23.8 (10) 21.2 (10)
% female controls (n) 25 (10) 25 (10) 26.1 (11) 28.5 (12) 25.5 (12)
% female subjects DS (n) 25 (10) 25 (10) 24.1 (10) 23.5 (10) 27.66 (13)
Age: mean years ± SD 60.3 ± 14.49 60.9 ± 13.8 57.2 ± 16.8 60.9 ± 15.6 58.1 ± 15.62
PMI: mean hours ± SD 44.36 ± 28.91 46.28 ± 28.8 45.58 ± 28.33 47.67 ± 30.58 43.69 ± 26.02
pH value: mean ± SD 6.52 ± 0.35 6.55 ± 0.33 6.47 ± 0.34 6.55 ± 0.36 6.56 ± 0.35
RIN value: mean ± SD 6.99 ± 1.81 6.58 ± 0.27 6.49 ± 1.89 6.62 ± 1.35 6.24 ± 1.02
ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; DRN, dorsal raphe nucleus; LC, locus
coeruleus; MRN, medullary raphe nucleus; PMI, postmortem interval; RIN, RNA integrity number.
Table 2. Raw cycle threshold (Ct) values ± SEM for samples
from the regions analyzed in male and female controls and
DS subjects
Region GAL GalR1 GalR2 GalR3
DLPFC 27.1 ± 0.2 25.7 ± 0.2 31.4 ± 0.2 33.2 ± 0.1
ACC 27.5 ± 0.1 28.6 ± 0.1 31.6 ± 0.2 33.5 ± 0.2
DRN 26.2 ± 0.4 27 ± 0.4 29.3 ± 0.2 31.5 ± 0.4
LC 24.6 ± 0.5 26.4 ± 0.6 32.3 ± 0.1 31.4 ± 0.6
MRN 25.2 ± 0.4 26.9 ± 0.4 34.6 ± 0.2 31.9 ± 0.4
ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex;
DRN, dorsal raphe nucleus; LC, locus coeruleus; MRN, medullary raphe
nucleus.
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regions. The most prominent receptor transcript overall is GALR1,
with up to eightfold differences in regional expression (dorsolateral
prefrontal cortex > anterior cingulate cortex). The GALR2 mRNA
level is high in the dorsal raphe nucleus and low in medullary raphe
nuclei. GALR3 mRNA follows the pattern of GAL with high levels
in the lower brainstem and low levels in cortex.
Expression of GAL and Its Receptors Is Altered in the Brains of DS
Subjects. In the dorsolateral prefrontal cortex, GAL mRNA levels
were significantly decreased in male DS subjects compared with
controls (P < 0.01) (Fig. 1A) and were significantly increased in fe-
male DS subjects (P < 0.05) (Fig. 1E), a distinct sex difference.
GALR1 mRNA levels were significantly increased in both male and
female DS subjects (P < 0.05) (Fig. S1 A and C). GALR3 mRNA
levels were significantly decreased in male (P < 0.01) (Fig. 2A) but
not in female (Fig. 2E) DS subjects. However, there were no sig-
nificant changes in GALR2 mRNA levels in either sex (Fig. S1 E
and G). In the anterior cingulate cortex, no significant changes in
GAL or its receptors were found (Fig. S2).
In the dorsal raphe nucleus and locus coeruleus, GAL mRNA
levels were significantly increased in both male (P < 0.01) (Figs. 3A
and 4A) and female (P < 0.01) (Figs. 3E and 4E) DS subjects. In-
terestingly, higher levels of tryptophan hydroxylase-2 (TPH2) mRNA
and immunoreactive neurons have previously been shown in the
dorsal raphe nucleus of suicides relative to normal controls
(63, 64). GALR1 mRNA levels were significantly increased only
in the dorsal raphe nucleus of male DS subjects (P < 0.05, Fig. S3
A and C) but were not increased in the locus coeruleus of these
subjects (Fig. S4 A and C). The expression levels of GALR3 were
significantly increased in both the dorsal raphe nucleus (Fig. 5 A
and E) and locus coeruleus (Fig. 6 A and E) in both sexes, more
robustly in females (female vs. males: P < 0.01 vs. P < 0.05). No
significant changes were found in GALR2 mRNA levels in these
two regions (Figs. S3 E and G and S4 E and G).
In the medullary raphe nuclei,GALmRNA levels were significantly
increased in both male and female DS subjects (P < 0.05) (Fig. S5 A
and C). In male DS subjects, the GALR1 expression levels were sig-
nificantly increased (P < 0.05) (Fig. S5E), whereas GALR2 mRNA
levels were significantly decreased (P < 0.01) (Fig. S5I). However,
there were no significant changes in female DS subjects. On the other
hand, the expression levels of GALR3 were significantly increased in
both sexes (P < 0.05) (Fig. S5 M and O). All mRNA changes are
summarized in Table 3.
The DNA Methylation Status of GAL and GALR3 Changes in the Brain
of DS Patients. In the dorsolateral prefrontal cortex, At the first
three CpG sites analyzed (CpG1–3, Fig. 1B–D), the percentage of
methylated DNA was significantly higher in male DS subjects than
in controls (P < 0.05, P < 0.01, and P < 0.01, respectively). In female
DS subjects, the methylation status was different among the CpG
sites, with a significant increase at CpG1 and a significant decrease
at CPG2 (P < 0.05) (Fig. 1 F and G, respectively), and with no
changes at CpG3 (Fig. 1H). No significant changes were found for
any of the receptors in this brain region (Fig. 2 B–H and Fig. S1) or
for any of the four markers in the anterior cingulate cortex (Fig. S2).
In the dorsal raphe nucleus, a significant decrease was seen in the
percentage of methylated DNA in the GAL promoter of male DS
subjects, but only at the CpG1 site (P < 0.05) (Fig. 3B), with no
changes in female DS subjects (Fig. 3 F–H). Interestingly, GALR3
was the only receptor that was significantly altered in the brains of DS
subjects in a sex-dependent manner. Thus, only female DS subjects
showed a significant decrease in the percentage of methylated DNA
at CpG1 and CpG2 sites (P < 0.01) (Fig. 5 F and G, respectively).
In the locus coeruleus the percentage of methylated DNA in the
GAL promoter at CpG1 and CPG2 was significantly decreased in DS
subjects (male: P < 0.01 and P < 0.05; female: P < 0.05 and P < 0.01)
(Fig. 4 B and C and F and G, respectively). There was a signif-
icant decrease in the percentage of methylated DNA at the
CpG1 site of theGALR3 gene in DS subjects of both sexes (P< 0.05)
(Fig. 6 B and F), whereas methylation at the CpG2 site was
significantly decreased only in female DS subjects (P < 0.01)
(Fig. 6G). No changes were found at the CpG3 site (Fig. 6D andH).
There were no significant changes in the methylation status of
GAL or its receptors in either the anterior cingulate cortex or the
medullary raphe nuclei (Figs. S2 and S5). All methylation changes
are summarized in Table 3. For the region including differentially
methylated CpG sites in GAL and GALR3, a number of potential
transcription factor-binding sites were identified using the JASPER
database (Fig. S6C) (65, 66).
Fig. 1. Alterations in GAL gene expression and DNA methylation in postmor-
tem dorsolateral prefrontal cortex (BA 8/9) of male and female DS subjects.
(A and E) Quantitative RT-PCR was used to examine the mRNA expression levels
of GAL in the dorsolateral prefrontal cortex of male (A) and female (E) controls
and DS subjects. The expression level of GAL was normalized to HPRT levels and
expressed relative to their respective control levels. (B–D and F–H) Bisulfite
pyrosequencing was used to quantify percentage of DNA methylation levels at
individual CpG sites of theGAL gene in male (B–D) and female (F–H) controls and
DS subjects. All data are presented as mean ± SEM; n = 10 per group. Significant
differences between DS subjects and controls are indicated: *P < 0.05, **P < 0.01.
CON, controls; DS, depressed suicide.
Fig. 2. Alterations in GALR3mRNA and DNAmethylation in the dorsolateral
prefrontal cortex (BA 8/9) of male and female DS subjects. (A and E) Gene-
expression levels of GALR3 in the dorsolateral prefrontal cortex of male (A)
and female (E) controls and DS subjects. (B–D and F–H) Percentage of DNA
methylation levels at individual CpG sites of the GALR3 gene in male (B–D)
and female (F–H) controls and DS subjects. All data are presented as mean ±
SEM; n = 10 per group. Significant differences between DS subjects and
controls are indicated: **P < 0.01. CON, controls; DS, depressed suicide.
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Increased Concentrations of GAL Protein in the Locus Coeruleus in
Female DS Subjects. The RIA monitors intracellular, vesicle-stored
GAL concentrations and not extracellular peptide, which is rapidly
degraded (67). The concentrations varied considerably among the
regions analyzed, with low and intermediate levels in the forebrain
and medullary raphe nuclei, respectively, and high and very high
levels in locus coeruleus and dorsal raphe nucleus, respectively
(Table 4). These results are reflected in the transcript levels. With
regard to differences between DS subjects and controls, significant
changes were only found in the female locus coeruleus (P = 0.025)
(Fig. S7I), where the mean concentration was 56% higher in DS
subjects than in controls (67.7 vs. 43.4 pmol/mg) (Table 4). In the
dorsolateral prefrontal cortex there was an apparent difference
between male and female controls, on the one hand, and male and
female DS subjects, on the other. However, the differences in the
mean and median concentrations of immunoreactive GAL did not
reach statistical significance (P < 0.05) using either logarithmically
transformed data in a parametric ANOVA or in a Kruskal–Wallis
nonparametric test on nontransformed data.
Discussion
The present study provides a comprehensive set of results suggesting
that the GAL system has an important role in MDD. The analysis of
postmortem brain samples from DS subjects and matched controls
reveals significant increases in transcription levels for GAL and
GALR3 with parallel decreases in DNA methylation in the locus
coeruleus in DS subjects of both sexes. A similar profile was seen in
the dorsal raphe nucleus samples, although the methylation changes
were found mainly for the female GALR3 transcript. In contrast, in
the forebrain GAL mRNA levels were decreased in the male but
were increased in the female, dorsolateral prefrontal cortex, with a
wide increase in methylation in the maleGAL gene. Some ways that
these changes in the locus coeruleus might influence the develop-
ment of MDD are illustrated in Fig. 7.
In addition, the present study reports markedly different tran-
script levels for the four GAL family members with individual, re-
gional distribution patterns.GAL andGALR1mRNAs are the most
abundant transcripts, GALR1 mRNA being expressed at eightfold
higher levels in dorsolateral prefrontal cortex than in anterior cin-
gulate cortex (Table 2). Finally, the RIA shows major differences in
GAL peptide levels among the brain regions analyzed, paralleling
transcript levels and evidencing translation of the transcript. How-
ever, a sex difference could be detected, but only in the locus
coeruleus, where levels were higher in females.
These results are discussed in relation to our previous in situ
hybridization analysis describing the cellular localization of the
galanin system in the lower brainstem (locus coeruleus and dorsal
raphe nucleus) of the normal human postmortem brain (32). This
approach can suggest which neuron populations express the
transcripts and are the site of the methylations, here reported
based on qPCR and bisulfite pyrosequencing, i.e., biochemical
analyses (see below). For a comparison of the results in LeMaître,
et al. (32) and the present study, see SI Discussion, Comparison of
in Situ Hybridization and RT-qPCR Results.
GAL and MDD: Genome-Wide Association Studies. Two recent large
genome-wide association studies (GWAS) (68, 69) have analyzed
in-depth cohorts of MDD patients and controls. The first study,
investigating 2,431 cases and 3,673 controls, found a suggestive
association of GAL with MDD using a gene-based test, which
retained low-association P values in two additional independent
cohorts (68). However, in the second GWAS involving 9,240
MDD cases and 9,519 controls (at that time the largest GWAS
conducted), no SNP achieved genome-wide significance in either
the MDD discovery or the replication phase (69).
In addition, two recent huge GWAS analyzing depressive
symptoms (70) and self-reported depression (71), with tens of thou-
sands participants, could not support a role of the galanin system
genes within their top results. However, these GWAS did not
control for the well-known environmental risk factors of de-
pression (72). In fact, in the study by Juhasz, et al. (56) galanin
system gene variants altered the development of depression only
in people who also were exposed to strong stress, and no significant
effect of GAL and its receptors could be seen without taking stress
into account (SI Discussion, GAL and MDD: GWAS).
GAL and MDD: Candidate Gene and Gene-Environment Approach. A
recent candidate gene analysis based on self-reported questionnaires
from 2,361 individuals (∼70% females; ∼30% males) measuring
lifetime depression, depressive and anxiety symptoms, and life
stressors showed that gene variants for GAL and all three of its
receptors are associated with increased risk of lifetime and current
Fig. 4. Alterations in GAL gene expression and DNA methylation in the
locus coeruleus of male and female DS subjects. (A and E) Gene-expression
levels of GAL in the locus coeruleus of male (A) and female (E) controls and
DS subjects. (B–D and F–H) Percentage of DNA methylation levels at indi-
vidual CpG sites of the GAL gene in male (B–D) and female (F–H) controls and
DS subjects. All data are presented as mean ± SEM; males: n = 10 controls, 10
DS subjects; females: n = 12 controls, 10 DS subjects. Significant differences
between DS subjects and controls are indicated: *P < 0.05, **P < 0.01. CON,
controls; DS, depressed suicide.
Fig. 3. Alterations in GAL gene expression and DNA methylation in the
dorsal raphe nucleus of male and female DS subjects. (A and E ) Gene-
expression levels of GAL in the dorsal raphe nucleus of male (A) and female
(E) controls and DS subjects. (B–D and F–H) Percentage of DNA methylation
levels at individual CpG sites of the GAL gene in male (B–D) and female (F–H)
controls and DS subjects. All data are presented as mean ± SEM; males: n =
11 controls, 10 DS subjects; females: n = 11 controls, 10 DS subjects. Signif-
icant differences between DS subjects and controls are indicated: *P < 0.05,
**P < 0.01. CON, controls; DS, depressed suicide.
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depression and anxiety, but only after childhood adversity or recent
negative life events, suggesting that the galanin system genes alter
the development of depression through epigenetic mechanisms
(56). In agreement with this study, the present report reveals cor-
relations, mainly for GAL and GALR3, between transcript levels
and promoter methylation in several brain regions of both sexes
(SI Discussion, GAL and MDD: Candidate Gene Approach).
DNA Methylation. Methylation changes for the galanin system
have been described previously, mainly in studies on various
types of cancer, and were associated with tumor suppression (73, 74).
Here we report that DNA methylation of members of the galanin
system also may play a role in MDD. Analyzing three or four se-
lected CpG sites, we observed significant changes in the degree of
methylation at several sites in the dorsolateral prefrontal cortex,
dorsal raphe nucleus, and locus coeruleus of DS subjects compared
with controls. The changes in receptor methylation were associated
withGALR3 in the locus coeruleus and dorsal raphe nucleus, mainly
in female subjects. With some exceptions, there was an inverse
correlation between methylation and transcript levels, in agreement
with the view that methylation represses gene transcription (75) (SI
Discussion, DNA Methylation).
Transcription Factor-Binding Analysis. In many cases, DNA meth-
ylation of specific CpGs influences transcription factor binding.
Using the JASPER database (65, 66), we identified a number of
potential transcription factor-binding sites in the regions including
the differentially methylated CpG sites in GAL and GALR3.
Two of the transcription factors, specificity protein 1 (SP1) and
NEUROD2, regulate GAL expression in mouse (76, 77) and
potentially also in human (78). Further, SP1 binding is known to
be affected by DNA methylation (79). Both transcription factors
potentially bind to CpG2, which was hypermethylated in male
and hypomethylated in female DS subjects, corresponding to
decreased and increased mRNA expression, respectively. An
additional SP1-binding site was identified in the region including
CpG1. For GALR3, the transcription factors binding to the
identified sites have not been shown to be involved in the regula-
tion of this gene. Taken together, these findings strengthen the
notion that the observed epigenetic and gene-expression changes
are connected and open the way for mechanistic studies to un-
derstand the regulation of these genes in depth.
Locus Coeruleus and Dorsal Raphe Nucleus. The locus coeruleus and
dorsal raphe nucleus regions in the rat lower brainstem harbor
NA and 5-HT cell bodies, respectively (80) and are key nodes in
the mood circuitry. Both the GAL and GALR3 transcripts in the
locus coeruleus samples are expressed mainly in the noradren-
ergic neurons (32); thus they are likely to be the sites for the
regulation of transcripts and the methylation shown in the
present study.
The dorsal raphe nucleus, where 50–70% of all neurons in
rodents are nonserotonergic (81–83), can be discussed in a
similar way: The monitored GAL and GALR1 mRNAs may not be
present in 5-HT neurons, but GALR3 likely is present. However,
both GAL and GALR1 transcripts have been observed in the close
vicinity of the 5-HT neurons (32). Thus the changes in GAL mRNA
and methylation likely occur in nonserotonin cells. Interestingly, the
up-regulation ofGALR1mRNA in the ventral periaqueductal gray is
in agreement with two recent experimental studies on male rats that
showed an increase in GALR1 mRNA levels (likely not in 5-HT
neurons) after mild, blast-induced traumatic brain injury (84) and
chronic mild stress (85). For a discussion of medullary raphe nuclei,
see SI Discussion, Medullary Raphe Nuclei. However, we note here
that in this region there is an increase inGAL andGALR3 transcript
Fig. 5. Alterations in GALR3 gene expression and DNA methylation in the
dorsal raphe nucleus of male and female DS subjects. (A and E) Gene-expression
levels of GALR3 in the dorsal raphe nucleus of male (A) and female (E) controls
and DS subjects. (B–D and F–H) Percentage of DNA methylation levels at indi-
vidual CpG sites of the GALR3 gene in male (B–D) and female (F–H) controls and
DS subjects. All data are presented asmean ± SEM; males: n = 11 controls, 10 DS
subjects; females: n = 11 controls, 10 DS subjects. Significant differences be-
tween DS subjects and controls are indicated: *P < 0.05, **P < 0.01. CON,
controls; DS, depressed suicide.
Table 3. Overview of mRNA and DNA methylation changes
GAL GALR1 GALR2 GALR3
gDNA methylation gDNA methylation gDNA methylation gDNA methylation
Regions Sex mRNA CpG1 CpG2 CpG3 mRNA CpG1 CpG2 CpG3 CpG4 mRNA CpG1 CpG2 CpG3 CpG4 mRNA CpG1 CpG2 CpG3
DLPFC M ↓↓ ↑ ↑↑ ↑↑ ↑ — — — — — — — — — ↓↓ — — —
F ↑ ↑ ↓ — ↑ — — — — — — — — — — — — —
ACC M — — — — — — — — — — — — — — — — — —
F — — — — — — — — — — — — — — — — — —
DRN M ↑↑ — ↓ ↑ — — — — — — — — — ↑ — — —
F ↑↑ — — — — — — — — — — — — — ↑↑ ↓↓ ↓↓ —
LC M ↑↑ ↓↓ ↓ — — — — — — — — — — — ↑ ↓ —
F ↑↑ ↓ ↓↓ — — — — — — — — — — — ↑↑ ↓ ↓↓ —
MRN M ↑ — — — ↑ — — — — ↓↓ — — — — ↑ — — —
F ↑ — — — — — — — — — — — — ↑ — — —
The arrows represent statistical significance; upward arrows signify increased in gene expression and methylation status, and downward arrows signify
decreased gene expression and methylation status. A single arrow represents P < 0.05, and two arrows represent P < 0.01. ACC, anterior cingulate cortex;
DLPFC, dorsolateral prefrontal cortex; DRN, dorsal raphe nucleus; LC, locus coeruleus; MRN, medullary raphe nucleus.
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levels in males and females and in GALR1 transcript levels in males
only, as well as a robust decrease inGALR2mRNA in males only; in
fact, this is the only region showing a change in this receptor tran-
script. No effects on DNA methylation were recorded.
Prefrontal Cortex.A number of symptoms and diagnostic markers
of MDD have been associated with prefrontal cortex, including
decreased gray matter volume, hypermetabolism, and spine
morphology (86). We observed distinct decreases in GAL and
GALR3 mRNA levels in the dorsolateral prefrontal cortex of DS
males, with increased methylation at three sites of theGAL gene,
the reverse of the effects seen in locus coeruleus and dorsal ra-
phe nucleus. In contrast, GAL mRNA is up-regulated in this
region in female DS subjects; this up-regulation is the only sex
difference for the GAL transcript seen in the qPCR analysis and
requires further analysis. However, no changes were detected in
another, closely related cortical area, the anterior cingulate
cortex, which also has been consistently implicated in depression
and suicide (87). Interestingly, although the average levels for
GAL, GALR2, and GALR3 transcripts are approximately similar
in the cortical regions, GALR1 mRNA levels are around eight-
fold higher in dorsolateral prefrontal cortex than in anterior
cingulate cortex.
The findings in the prefrontal cortex are difficult to interpret,
because we have no information on the cells expressing GAL
system members in human dorsolateral prefrontal and anterior
cingulate cortices. In principle, however, the mechanistic effects
of GAL release should be equally mediated by GAL1 and GAL3,
because both exhibit a similar (nanomolar) affinity for GAL (88).
Therefore the differences will depend on which neuron subtype
expresses the receptor and on the coupling to intracellular
signaling cascades.
In general, peptides in the cortical region are detected in in-
terneurons (89), but many pyramidal neurons express the transcript
for cholecystokinin (90) and the peptide itself (91). Quantitative
autoradiographic 125I-GAL–binding studies showed a strong corti-
cal binding in the human brain (39, 41), in sharp contrast with the
rat brain, which lacks 125I-GAL binding in dorsal cortical and
hippocampal areas (37, 38). However, 125I-GAL(1-15ol) binds to
these regions (92), and GAL(1-15) hyperpolarizes hippocampal C3
neurons (93). Investigation of these findings is continuing (SI
Discussion, Dorsolateral Prefrontal Cortex) (94).
As for the mechanism(s) involved, one may speculate that the
increased GAL mRNA levels in the locus coeruleus result in up-
regulated GAL synthesis, enhanced centrifugal, axonal GAL
transport, and increased GAL release in dorsolateral prefrontal
cortex (Fig. 7). Here, in a possibly desensitizing process, GAL
may down-regulate GALR3 expression in cortical projections
and/or interneurons.
Functional Significance. It has been suggested that epigenetic
mechanisms, such as DNA methylation, may be involved in
psychiatric disorders (95, 96) and play an important role in stress
and depression (7, 97). Here CpG methylation, catalyzed by
DNA methyltransferases, in general represses gene transcription
(75). We focus the discussion on the NA/locus coeruleus system
and the prefrontal cortex. The role of NA vs. GAL has been
discussed by Kuteeva, et al. (54).
Animal Studies in the Locus Coeruleus. Early experimental evidence
suggested that locus coeruleus neurons in rats are activated by
stress, resulting in increased NA synthesis and NA release in the
forebrain (98–100). Stress also increases GAL expression in this
nucleus (101, 102). In general terms neuropeptides are released
following increased/burst firing (103, 104), also in the forebrain
(105, 106). Thus, stress and increased/burst firing likely causes
GAL release from nerve terminals in the forebrain as well as from
soma/dendrites of the locus coeruleus neurons. Peptide release
from soma/dendrites was first shown for oxytocin/vasopressin in
magnocellular neurons in the hypothalamic paraventricular nu-
cleus (107) and may be relevant for GAL in the locus coeruleus
also (108).
Rat locus coeruleus neurons express GALR1 mRNA (42, 43),
and, as evidenced by electrophysiological studies (109), this re-
ceptor is likely functional in this site, mediating hyperpolarization
(46, 110). Thus, somato-dendritically released GAL may inhibit
firing via a GAL1 autoreceptor, hypothetically to prevent over-
excitation (54). In agreement, results from a study on a transgenic
mouse overexpressing GAL under the dopamine β-hydroxylase
promoter with a fivefold increase in GAL mRNA in the locus
coeruleus (111) suggest that GAL is important for modulating
anxiety states driven by high noradrenergic signaling (112).
The Human Locus Coeruleus. In trying to translate the animal ex-
perimental scenario to humans and MDD, one could argue that
Fig. 6. Alterations in GALR3 gene expression and DNA methylation in the
locus coeruleus of male and female DS subjects. (A and E) Gene expression
levels of GALR3 in the locus coeruleus of male (A) and female (E) controls
and DS subjects. (B–D and F–H) Percentage of DNA methylation levels at
individual CpG sites of the GALR3 gene in male (B–D) and female (F–H)
controls and DS subjects. All data are presented as mean ± SEM; males: n =
10 controls, 10 DS subjects; females: n = 12 controls, 10 DS subjects. Signif-
icant differences between DS subjects and controls are indicated: *P < 0.05,
**P < 0.01. CON, controls; DS, depressed suicide.
Table 4. Concentration of GAL (picomoles per milligram ± SEM) in the different regions
analyzed by RIA
Subject DLPFC ACC DRN LC MRN
Male controls 3.89 ± 1.21 5.35 ± 1.15 61.58 ± 13.74 31.80 ± 7.46 15.65 ± 2.32
Male DS subjects 2.68 ± 0.52 4.94 ± 0.96 68.14 ± 11.6 37.39 ± 10.71 18.73 ± 4.76
Female controls 1.70 ± 0.38 6.37 ± 1.79 80.62 ± 10.24 43.35 ± 6.33 15.45 ± 3.53
Female DS subjects 1.33 ± 0.29 5.97 ± 1.32 81.61 ± 5.19 67.68 ± 7.47 13.55 ± 2.95
ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; DRN, dorsal raphe nucleus; LC, locus
coeruleus; MRN, medullary raphe nucleus.
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(i) GAL3 seems to have replaced GAR1 in human locus coeruleus
neurons (32); (ii) hyperpolarization is one transduction mechanism
for GAL1 and also may be the transduction mechanism for GAL3
(46, 88, 110); and (iii) GAL and GALR3 transcripts are increased
in the locus coeruleus of DS subjects’ brains. It may be speculated
that chronic stress and, as a consequence, constant and persistent
inhibition of the NA-locus coeruleus neurons by GALmay result in
reduced NA levels in the forebrain regions involved in mood
control, e.g., the dorsolateral prefrontal cortex and anterior cin-
gulate cortex; reduced NA levels are a characteristic feature of
mood-related disorders. Together with a genetic vulnerability (lack
of resilience), this reduction in NA levels may contribute to the
symptoms encountered in such disorders (Fig. 7).
Prefrontal Cortex. In the prefrontal cortex, reciprocal interactions
between the dorsolateral prefrontal cortex and anterior cingulate
cortex, as well as between the anterior cingulate cortex and amyg-
dala, have been described, whereby MDD subjects show reduced
functional connectivity between the dorsolateral prefrontal cor-
tex and anterior cingulate cortex (87). The transcript levels of all
four GAL members are very similar in the two regions, except
that (i) GALR1 mRNA levels are eightfold higher in the
dorsolateral prefrontal cortex than in the anterior cingulate cortex
and (ii) the differences between MDD and controls are mainly
for GAL and are found only in male dorsolateral prefrontal
cortex, indicating that any prefrontal cortical GALergic mecha-
nisms in MDD are associated with GAL and GALR3 in this
region and sex (SI Discussion, Dorsolateral Prefrontal Cortex). Of
note, the apparent differences in GAL concentrations in this
region between normal male and female controls did not reach
significance but may still be taken as support for sex having an
influence on information processing in this cortical region.
Treatment of MDD with Neuropeptides. Neuropeptide receptors may
be promising targets for drug development in general because, as
mentioned previously, they are primarily released upon high-
frequency/burst firing (103, 104) that may occur in a selectively chal-
lenged, pathologically afflicted system (16, 113). Therefore,
the antagonist will block only an overactivated signaling pathway, not
affecting other silent or moderately active (no peptide release) systems
producing the same ligand, and thus resulting in fewer side effects.
Treatment of depression with neuropeptide antagonists has
been considered previously (15–19, 114). In fact, an initial report
on the administration of a substance P/neurokinin 1 antagonist
showed a significant efficacy vs. placebo, without side effects
(115). This result could not be reproduced in an expanded phase
3 study (15, 116); however, clinical work on neurokinin antago-
nists is ongoing (117, 118).
Treatment of MDD with GAL Ligands. Both GAL and GAL3 are up-
regulated in the locus coeruleus and dorsal raphe nucleus of MDD
patients, possibly resulting in attenuated NA and 5-HT release in the
forebrain. Treatment with a GAL3 antagonist could, by disinhibition,
have antidepressant activity, restoring NA and 5-HT levels in these
brain regions, just as SNRIs do. Moreover, it may be speculated that
the well-known delay in the onset of SSRIs’ effect caused by the
activation of somatic, inhibitory 5-HT1A receptors (8, 58) may not
occur with GAL3 antagonists. Also, GAL3 signaling in some other
brain regions, e.g., the dorsolateral prefrontal cortex, likely will not
be affected, because our study shows thatGAL andGALR3mRNA
are unchanged (in females) or even down-regulated (in males),
possibly excluding GAL system-related side effects. Moreover, the
regionally selective effect of a GAL3 antagonist should compare
favorably with SSRIs, SNRIs, and NRIs, which increase extracellular
monoamine levels in all regions that monoamine neurons innervate,
i.e., essentially throughout the entire nervous system. In fact, small-
molecule, blood–brain barrier-penetrating GalR3 antagonists have
been generated (119, 120). The extent to which such an antagonist
would act via mechanisms different from those of SNRIs and
Fig. 7. The locus coeruleus (LC) pathway to cortex and its involvement in stress. Many neurons in the locus coeruleus coexpress NA and GAL. In rats, under normal
circumstances these neurons fire spontaneously in a slow and regular fashion (124), but in response to stress they react with increased activity and burst firing (100).
NA is stored primarily in synaptic vesicles and is released at low activity and more so after stress (98, 99), acting on adrenoreceptors (ARs). GAL is stored only in large,
dense core (LDC) vesicles and is released extrasynaptically (125) in response to increased/burst firing (106) from these vesicles in nerve endings in the forebrain. In
humans (this study), GAL may, e.g., activate inhibitory postsynaptic GAL1 receptors (GalR1) on neurons in the dorsolateral prefrontal cortex (DLPFC) and anterior
cingulate cortex (ACC). Presumably, release also can occur from dendrites/soma in the locus coeruleus, activating inhibitory GAL3 autoreceptors (GalR3). It is hy-
pothesized that under excessive/chronic stress GAL induces a long-lasting inhibition of NA neurons and thus of NA release in forebrain regions such as the dor-
solateral prefrontal cortex and anterior cingulate cortex, contributing to the development of MDD. Not included are changes in GAL, GALR1, and GALR3 mRNA
levels in the dorsolateral prefrontal cortex.
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whether the currently used antidepressant drugs act via the GAL
system has been discussed (121).
Limitations. Several limitations are associated with the present
study. They are discussed in some detail in SI Discussion, Limi-
tations and encompass (i) concerns about GAL3, including its
transduction mechanism(s) [this receptor has emerged as a
complex receptor lacking well-defined signaling properties,
contrasting GAL1 and GAL2 (36); so far there is no evidence
that GAL3 is involved in receptor di- or heterodimerization
(45)]; (ii) the lack of information about the protein, because only
the transcripts for the receptors have been studied; (iii) the
modest, albeit significant, changes in transcript mRNA levels;
(iv) the relatively low number of postmortem brains analyzed;
(v) the incomplete knowledge (in some instances) of the identity
of the neurons expressing the transcripts (and thus of the site
where methylation occurs); for example, the study by Le Maître,
et al. (32) was not systematic, and galanin–5-HT coexistence in
regions not analyzed cannot be excluded; and (vi) the general
low sensitivity of histochemical techniques; this low sensitivity
may have been an issue when Le Maître, et al. (32) could not
detect the GAL1 transcript in the locus coeruleus with in situ
hybridization, whereas the present qPCR analysis showed high
levels of this transcript in this region; (vii) the superficial in-
vestigation of methylation sites and their functional significance;
and (viii) the influence of treatment with various drugs (Table
S1), which requires further investigation (also see ref. 121).
Concluding Remarks. The present results, based on the analysis of
five human brain regions, suggest the GAL system is involved
in MDD. Interestingly, exactly 40 y ago Asberg and colleagues (122)
reported that significantly lower concentrations of the 5-HT me-
tabolite 5-hydroxyindoleacetic acid (5-HIAA) in the cerebrospinal
fluid are associated with a very high rate of serious suicidal attempts,
opening the way for the development of SSRIs aimed at elevating
extraneuronal 5-HT levels. This class of drugs then replaced the
monoamine oxidase inhibitors and the tricyclic antidepressants.
It is important to note that many overlapping transmitter
systems exist and, in a way similar to the GAL family, may be in-
volved in MDD psychopathology. The available detailed knowledge
of the cellular organization and transmitter receptor architecture of
the human prefrontal cortex, two subregions of which are studied
here, provides a broad perspective on the present work and also
shows how much research still needs to be carried out (123).
Materials and Methods
Brain Samples. Postmortem brain tissue was obtained from the Douglas-Bell
Canada Brain Bank. A total of 212 punched samples from five different brain
regions was included (Table 1). Ethical approval for this study was obtained
from the Institutional Review Board of the Douglas Mental Health University
Institute, with written informed consent from the families. The Regional Ethical
Board in Stockholm has granted The Karolinska Institutet group permission
no. 2013/474-31/2 for processing postmortem brain samples (SI Materials and
Methods, Brain Samples and Table S1).
RNA Isolation and Integrity Analysis. Total RNA was isolated using the RNeasy
PlusMini Kit. RNAquantity andqualitywere determined spectrophotometrically
by using a ND1000 nanodrop. RNA integrity was checked using Experion au-
tomated electrophoresis system (Bio-Rad Laboratories). Total RNA was reverse
transcribed to generate cDNA using a High-Capacity Reverse Transcription Kit
(Life Technologies) (SI Materials and Methods).
RT-qPCR. qPCR was performed as described previously (SI Materials and
Methods) (32).
Genomic DNA Extraction and PyroMark PCR. Genomic DNA (gDNA) was isolated
by using the DNeasy Blood and Tissue Kit (Qiagen), checked spectrophoto-
metrically, and bisulfite-converted by using the EZ DNA Methylation-Gold Kit
(Zymo Research). Converted DNA was subject to 40 cycles of amplification by
using gene-specific primers and the pyroPCR PyroMark (Qiagen) kit (SIMaterials
and Methods).
Bisulfite Pyrosequencing. Bisulfite pyrosequencing was performed using
PyroMark Q96 ID (Qiagen) according to the manufacturer’s protocol and as
previously described (122). Primer sequences are listed in Fig. S6B, and the ge-
nomic locations of the CpGs analyzed are shown in Fig. S6A; also see SI Ma-
terials and Methods.
RIA. Human GAL was measured using antiserum G-026-01 (Phoenix Europe
GmbH) raised in a rabbit against human GAL (SI Materials and Methods).
Statistical Analysis. Statistical analysis was performed with GraphPad Prism 6
(GraphPad Software), StatView (SAS Institute Inc.), and Systat 11 (Systat
Software, Inc.). RIN, age, PMI, and tissue pH values for the five brain regions in
controls and DS subjects were analyzed bymultivariate ANOVA and two-tailed t
test for independent groups. The Shapiro–Wilks test was used to test for
Gaussian distribution. Significant outliers for qPCR fold change and percent
methylation were analyzed by the ROUT (robust regression followed by outlier
identification) method and were excluded if P < 0.05. qPCR data were analyzed
by using the nonparametric Mann–Whitney U test. Differences in DNA meth-
ylation between controls and suicides were analyzed using the Mann–Whitney
U test. P values below 0.05 were considered significant, and P values between
0.05 and 0.1 were considered to represent a trend.
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SI Materials and Methods
Brain Samples. Postmortem brain tissue was obtained by collab-
oration with the Quebec Coroner’s Office and the Suicide Section of
the Douglas-Bell Canada Brain Bank (Douglas Mental Health
University Institute, Montreal, Quebec, Canada). A total of 212
punched brain samples from five different regions of 61 individuals
(controls and DS subjects) were included (Table 1 and Table S1). All
individuals were of French-Canadian origin, a homogeneous pop-
ulation, and samples were matched for PMI (the interval between
death and freezing of the brain), subject age at death, and tissue pH.
Psychological autopsies were performed as described previously for
both DS subjects and controls, and diagnoses were established by a
panel of psychiatrists based on Diagnostic and Statistical Manual of
Mental Disorders, edition 4 (DSM-IV) criteria. Subjects in the control
group had died suddenly from accidental or natural causes. Samples
were obtained from five different brain regions: dorsolateral pre-
frontal cortex Brodmann area (BA 8/9), anterior cingulate cortex
(BA 24), dorsal raphe nucleus, locus coeruleus, and the medullary
raphe nuclei.
Brains fromDS subjects and controls underwent a process known
as a “psychological autopsy” to retrieve phenotypic information.
This proxy-based interview procedure is the accepted standard for
obtaining diagnostic information postmortem. Briefly, a few months
following death, subjects’ families were contacted, and the person
best acquainted with the deceased was recruited to undergo a series
of structured interviews. These interviews were supplemented with
information from archival material obtained from hospitals, the
coroner’s office, and social services. Following the interviews, clin-
ical vignettes were produced and assessed by a panel of clinicians to
generate DSM-IV diagnostic criteria. As detailed elsewhere (126),
the psychological autopsies provide socio-demographic character-
istics, social developmental history, DSM-IV axis I diagnostic in-
formation, and behavioral traits. We also obtain toxicological
assessments and complete information on medication prescription.
The dorsal raphe nucleus and locus coeruleus were dissected
using the following coordinates from a human brainstem atlas
(127): dorsal raphe nucleus from Obex +32 to +39, locus coeruleus
from Obex +24 to +31, and medullary raphe nuclei (obscurus and
magnus raphe) from Obex 0 to +16. It should be noted that the
samples labeled “locus coeruleus” and especially those labeled
“dorsal raphe nucleus” include many different neuron populations
that are not noradrenergic or serotonergic, respectively.
Ethical approval for this study was obtained from the Insti-
tutional Review Board of the Douglas Mental Health University
Institute, and written informed consent was obtained from the
family of each deceased subject before inclusion in the study. The
Regional Ethical Board in Stockholm has granted The Karolinska
Institutet group permission no. 2013/474-31/2 for processing
postmortem brain samples.
RNA Isolation and Integrity Analysis.Total RNA from each of the 212
samples was isolated using the RNeasy Plus Mini Kit (Qiagen). RNA
quantity and quality were determined spectrophotometrically by using
a ND1000 nanodrop (Saveen Werner). RNA integrity was checked
using an Experion automated electrophoresis system (Bio-Rad). All
samples that showed a RIN higher than 5 were considered good-
quality RNA samples, and samples with a RIN higher than 8 were
considered as perfect (128). Samples with very low RNA concen-
trations and integrity (RIN <4) were excluded from the RT-qPCR
analysis (n = 27 of 212 punched samples). Total RNA was reverse
transcribed to generate cDNA using a High-Capacity Reverse
Transcription Kit (Life Technologies) according to the manufac-
turer’s instructions.
RT-qPCR.RT-qPCRwas performed as described previously (32) with
some modifications. Briefly, 500 ng of RNA was reverse transcribed
using the High-Capacity Reverse Transcription Kit (Life Technol-
ogies) with the cDNA subjected to 40 cycles of amplification and by
using TaqMan gene-expression assays and TaqMan PCR Master
Mix (Life Technologies) using the 7500 FastReal-TimePCRSystem
(Life Technologies). cDNA samples were loaded in duplicate, and
the expression assays used four markers of the GAL system (GAL
and the galanin receptor subtypes GALR1–3) in addition to the
endogenous controls. Random samples were cloned into PCR II
TOPO TA cloning vector (Life Technologies) and were sequenced
at KIGene, Karolinska Institutet to confirm the specificity of the
amplification reactions. A no-template control (NTC) reaction and
an RT control reaction were used to check for unspecific amplifi-
cation and amplification from gDNA, respectively. Relative fold
changes were calculated by the comparative Ct method (2−ΔΔCT).
gDNA Extraction and PyroPCR. gDNA from the 212 samples of the
five regions was isolated using the DNeasy Blood and Tissue Kit
(Qiagen). The quality and quantity of the isolated gDNA was
checked spectrophotometrically, and 400 ng of gDNA from each
sample was bisulfite-converted using the EZ DNA Methylation-
Gold Kit (ZymoResearch). Onemicroliter of the convertedDNA
was subjected to 40 cycles of amplification using gene-specific
primers and the pyroMark PCR kit (Qiagen). Details of the
forward and biotinylated reverse primers are given in Fig. S6B.
One-fifth of the PCR product was checked for specific amplifi-
cation on 2% agarose gel by electrophoresis, and the remainder
was used for bisulfite pyrosequencing.
Bisulfite Pyrosequencing. Bisulfite pyrosequencing was performed
using PyroMark Q96 ID (Qiagen) according to the manufac-
turer’s protocol and as previously described (129). Briefly, PCR
products were mixed with binding buffer (Qiagen) and Sephar-
ose beads (Sarstedt) with constant shaking using the Thermomixer
Model 5350 Incubator shaker (Eppendorf) at 200 rpm for 10 min. In
parallel, sequencing plates were loaded with sequencing primers for
GAL and its receptors’ genes and annealing buffer. The vacuum
workstation also was prepared with the buffers required for the
washes. After mixing, vacuum was applied, and the PCR primers
bound to the Sepharose beads were aspirated using the filter
probes. The filter probes were flushed for 5 s in 70% ethanol, 10 s
in denaturation buffer (Qiagen), and 10 s in wash buffer
(Qiagen). With vacuum ON, the tool was raised beyond 90°
vertical for 5 s; then, with vacuum OFF, the filter probes were
lowered into the sequencing plate and agitated mildly to release
the beads into the wells. The samples were heated at 80° for
2 min and then were cooled to room temperature for 5 min. Then
the plate was processed for sequencing. The methylation percent-
age at each CpG site was analyzed using the PyroMark Q96 software
(Qiagen).
RIA. Human GAL was measured using antiserum G-026-01
(Phoenix Europe GmbH) raised in a rabbit against human GAL and
cross-reacting 100% to porcine and ratGAL. It has no cross-reactivity
to secretin, neuropeptide tyrosine (NPY), vasoactive intestinal
polypeptide (VIP), peptide histidine-methionine (PHM-27), or
GAL message-associated peptide [GMAP(1–41)]. HPLC-puri-
fied 125I-human GAL (Bachem) was used as the radioligand,
and human GAL (Bachem) was used as the calibrator. Sac-Cel
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(IDS, Ltd.) was used to separate bound and free fractions. Tissue
samples were weighed on a microscale and extracted in 1 mL
boiling 1 mol/L acetic acid for 10 min before sonication and ly-
ophilization. The pellet was resuspended in RIA buffer by son-
ication. The tissue concentrations of GAL were influenced
significantly by brain-specific regions (P < 0.001) but not by sex
(P = 0.157). The Shapiro–Wilks test found a non-Gaussian dis-
tribution in data from the anterior cingulate cortex but not from
other brain regions. Therefore nontransformed data were used.
SI Discussion
Comparison of in Situ Hybridization and RT-qPCR Results. mRNA
levels were monitored with RT-qPCR in the present study and by
in situ hybridization and RT-qPCR in the study by Le Maître,
et al. (32). With regard to in situ hybridization, it is clear that, at
least in rodents, the GAL system, especially the receptors and
certainly GALR2 and -3, represent low-abundance transcripts: In
the Allen Brain Atlas study (on mouse) no results were reported
for GALR3, and only incomplete results for GALR2 mRNA
(82). In agreement, the histochemical analysis of human brain
requires high-quality tissue samples, i.e., short PMIs: We could
see a signal for GALR1 and -3 only in samples with a PMI lower
than 4 h (32).
With regard to RT-qPCR, it is obvious that the raw Ct values
(cycle numbers) are lower in the present study than in the study by
Le Maître, et al. (32); i.e., the sensitivity of the present study is
higher. We believe this higher sensitivity results from several
modifications of the procedure. Namely, RT-qPCR was carried
out on a 7500 fast real-time PCR system (Applied Biosystems);
also, the PCR plates used in this study had a higher refractive
index, and therefore the raw Ct values of the markers were lower
in general. The kit used for reverse transcription also was dif-
ferent (SI Materials and Methods). Furthermore, this study used a
macrodissection procedure for the brainstem regions of dorsal
raphe nucleus and locus coeruleus rather than the microdissec-
tions used by Le Maître, et al. (32).
The forebrain was analyzed in both papers. However, the extent
to the areas described as “frontal cortex” and “cingulate cortex”
by Le Maître, et al. (32) really are comparable to “dorsolateral
prefrontal cortex, BA 8/9” and “anterior cingulate cortex, BA
24” in the present study cannot be determined at this point. Even
if the forebrain Ct values are much lower overall in the present
study, the ranking between the receptors remains the same, with
large (up to 32-fold) differences: GALR1 > GALR2 > GALR3.
However, a difficult-to-explain difference is the low expression
of GALR1 in dorsal raphe nucleus and locus coeruleus in the
earlier study compared with considerably higher levels found in
the present study. One possible explanation is the method of
dissection, with the present study encompassing a larger region
than the dorsal raphe nucleus and locus coeruleus isolated by
microdissection from frozen sections (32). It is possible that the
locus coeruleus and dorsal raphe nucleus proper and the locus
coeruleus have lower GALR1 and -2 but higher GALR3 mRNA
levels than the surrounding region included in the present study.
Comparing the RT-qPCR and in situ hybridization results is
complex. In the in situ hybridization analysis we never succeeded
in generating a working probe for GALR2, although one of the
cloned probes was positive after sequencing. The reason for this
lack of success could be inefficient hybridization of the GalR2
riboprobe or levels that were too low to be recorded and fell
below the detection limit of in situ hybridization. The GALR1
probe worked, both in the dorsal raphe nucleus and locus co-
eruleus sections. However, there was no evidence for the co-
existence of NA and 5-HT neurons. With the low GALR1
mRNA signal in the earlier study, we accepted the fairly weak in
situ hybridization signal, but, considering the robust mRNA
levels now obtained, it seems surprising that we did not see a
stronger signal. However, the GALR1 riboprobe may not have
hybridized optimally, in contrast with the GALR3 probe (32).
GAL and MDD: GWAS. Two recent large GWASs (68, 69) have
analyzed in-depth cohorts of MDD patients and controls. The
first, investigating 2,431 cases and 3,673 controls, obtained a
suggestive association ofGAL with MDD using a gene-based test
that retained low-association P values in two additional independent
cohorts (68). The most associated SNP found in GAL (rs2156464,
P = 2.7 × 10−5) is located in the haplotype block that has been
identified as being associated with panic disorder (130). This
haplotype block is in close proximity to the GAL CpG island,
suggesting that epigenetic mechanisms may play a role in both
disorders.
The secondGWAS, the largest conducted so far, involved 9,240
MDD cases and 9,519 controls. No SNP achieved genome-wide
significance in either the MDD discovery or the replication phase
(69) although in the galanin system genes some SNPs (e.g., GAL
rs2156464 P = 0.022) showed nominally significant associations
with MDD. Thus, the interesting findings reported by Wray,
et al. (68) could not be supported by further evidence.
In addition, two recent huge GWAS studies, with tens of
thousands participants, analyzing depressive symptoms (70) and
self-reported depression (71) could not reinforce the role of the
galanin system genes within their top results. However, self-
reported depression showed GWAS-level associations with genes
encoding transcription factors that are important in brain de-
velopment (131), whereas variants regulating gene expression in
the central nervous system were most abundant in the analysis of
depressive symptoms (70). These latter results emphasize that
dynamic changes in gene expression (frequently governed by
environmental factors) have a major role in the development of
depression. However, these GWAS studies were not controlled
for the well-known environmental risk factors of depression (72).
GAL and MDD: Candidate Gene Approach. A recent candidate gene
analysis based on self-reported questionnaires from 2,361 individuals
(∼70% females and∼30%males) (56), measuring lifetime depression,
depressive and anxiety symptoms, and life stressors, showed that
gene variants for GAL and all three of its receptors are associ-
ated with increased risk of lifetime and current depression and
anxiety following childhood adversity or recent negative life
events. Seven of the 12 haplotype tag SNPs investigated were
statistically associated with one or more of the three clinical
phenotypes, and six of these SNPs acted through interaction with
either childhood adversity or recent negative life events. In line
with these results, a system-level statistical analysis considering
the whole galanin system demonstrated that genetic variations in
the GAL and GALR1–3 genes were more relevant in those who
experienced severe life stresses than in those who did not, again
emphasizing the importance of potential epigenetic mechanisms.
Specifically, in the case of early childhood adversity, GALR1 was
highly relevant, whereas experiencing recent negative life events
increased the relevance of GAL and GALR1–3 genes, especially
GALR2 and GALR3. The investigated haplotype tag SNPs tagged
several functional variants within the galanin system that influence
the transcriptional or translational activity of the genes, including
transcription-binding sites (e.g., GAL rs3136540, rs3136541; GALR1
rs11662010; GALR2 rs8836; and GALR3 rs2017022), miRNA-
binding sites (e.g., GAL rs3136541; GALR1 rs11665337; and
GALR2 rs8836), and CpG islands (e.g., GALR1 rs5375) dem-
onstrated by the SNP Function Prediction tool (snpinfo.niehs.nih.
gov/snpinfo/snpfunc.php). In agreement with this previous study,
the present report reveals often robust correlations, in several brain
regions and in both sexes, between transcript levels and promoter
methylation, mainly for GAL and GALR3.
It is now established that a functional polymorphism in the
promoter region of the serotonin transporter, 5-HTTLPR, is associated
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with anxiety-related traits and susceptibility for depression (71,
132). Our subsequent analysis suggests that this effect may be
mediated in part by the GAL system and that the effect of this
system on stress-induced depressive systems is at least as strong
as that of the SERT functional polymorphism (56).
DNA Methylation. Changes in methylation for the galanin system
have been described previously, mainly in studies on various types
of cancer and in association with tumor suppression. For example,
hypermethylation (inactivation) of the GAL and/or GALR1 and
GALR2 genes in head and neck (73, 133, 134) and endometrial
(74) cancer is related to poor survival, indicating the importance
of these galanin genes for survival and a potential biomarker
function. Moreover, mice lacking de novo DNA methyltransferase
(Dnmt3a) have a metabolic syndrome-like phenotype and a highly
up-regulated expression of GAL (and tyrosine hydroxylase) in the
hypothalamic paraventricular nucleus (135).
Here we report that, in agreement, methylation of members of
the GAL system also may play a role in MDD. Thus, analyzing
four selected CpG sites, we observed significant changes in the
degree of methylation at several sites in the galanin promoter in
the dorsolateral prefrontal cortex, dorsal raphe nucleus, and locus
coeruleus of DS subjects compared with controls. For the receptors,
methylation changes compared with controls were found in the
promoter of GALR3 only in the dorsal raphe nucleus and locus
coeruleus, mainly in female subjects. With some exceptions, there
was an inverse correlation between methylation and transcript
levels. The effects observed are mostly robust. These results are in
agreement with methodological studies on the methylation state of
DNA extracted from human post mortem brains of patients,
showing that there is no correlation between DNA methylation
state and pH and suggesting that DNA methylation is stable (136).
Moreover, recent experiments on animal models report that
microRNA is very resistant, whereas RNA degradation is tran-
script specific, and that housekeeping genes are more robust than
genes with low expression (137).
Medullary Raphe Nuclei. A remark on the GAL system in the
medullary raphe nuclei: We included this brain region as a control,
because in the rat many 5-HT neurons in the medullary raphe and
adjacent nuclei: nucleus raphe pallidus, nucleus raphe obscurus,
nucleus raphe magnus (B1–3 cell clusters) (80) also express GAL
(28), but we considered them unlikely to be important for mood
regulation. Of note, in this brain region nothing is known about
GAL-receptor mRNAs in the rat or about the GAL cell bodies and
receptors in humans. Perhaps surprisingly, we found increased GAL
and GALR3 mRNA levels in both males and females, and in males
we found an increase in GALR1 and a decrease in GALR2 tran-
script levels; these are the only change in GALR2 seen at any brain
region studied. These alterations in transcripts suggest that GAL
and GalR3 may be regulated in a system not directly related to
MDD.Whether these two molecules are expressed in 5-HT neurons
remains to be analyzed. Nevertheless, these receptors, in addition
to those associated with NA neurons in the locus coeruleus and with
5-HT neurons in the dorsal raphe nucleus, would be affected by
treatment with GAL3 antagonists.
Dorsolateral Prefrontal Cortex. Interestingly, binding the dorso-
lateral prefrontal cortex was seen with autoradiography in the rat
using 125I-Gal(1–15ol) as ligand (92), a finding that has led to
further exploration of this N-terminal fragment in hippocampal
and mood function. Xu, et al. (93) reported a yet-to-be-cloned
GAL(1–15)-selective hyperpolarizing receptor on CA3 neurons
in the dorsal hippocampus. Strong depression-related and anxio-
genic-like effects were observed after intrahippocampal administra-
tion of GAL(1–15), likely involving GAL1–GAL2 heterocomplexes
(138) and possibly acting via enhancement of the antidepressant
effect induced by 8-OH-DPAT via 5-HT1A receptors (94).
However, a distinct difference is that there are no changes at all
in methylation in any of the receptors in cortical regions.
Limitations. We call attention to the following limitations:
i) The results highlight, in particular, GAL3, which is a complex
receptor (36) not found in all mammals (139). Its signaling
properties are still not well defined; althoughGALR3-transfected
cell lines have been generated (140, 141, 142), these cells
could not, thus far, be used for stable signaling experiments
(36) Still, GAL3 presumably acts via a pertussis toxin-sensi-
tive Gi/o-type G protein, which in turn regulates inwardly
rectifying K+ channels (88), similar to GAL1 receptors (88).
This lack of information contrasts sharply with our pro-
found knowledge about GAL1 and GAL2 (36).
ii) A further obstacle is that the main thrust of the analysis is
on transcripts, thus making statements about the translational
products, i.e., the proteins, uncertain. It is difficult to analyze
the receptor proteins, because generating reliable antibodies
to GAL receptors has been problematic (143).
iii) The effects on transcript levels are not dramatic (up to two-
fold), but modest effects are also seen in animal stress models:
In a rat chronic social stress model, a 75%increase in tran-
script level was seen in the locus coeruleus after 13 d (101); a
similar increase was seen 24 h after a saline injection in rats
(54); after 8 wk of chronic mild stress there was no increase at
all in mice (85); a 90% increase was recorded 2 h after a mild
blast traumatic injury in rats (84). These modest changes
could be compared with the dramatic and acute up-regulation
of GAL in dorsal root ganglia after peripheral nerve injury,
where protein levels increase by 120× after 3 d with a corre-
sponding increase in mRNA levels (144).
iv) The number of subjects is still limited. Of note, here we look
at actual brain tissue-specific epigenetic changes, whereas
the genetic analysis is based on stable DNA variants from
blood samples.
v) The results in Le Maître, et al. (32) indicate that 5-HT and
GAL in human dorsal raphe nucleus are not synthesized in
the same neurons. However, the previous study was not
systematic, i.e., encompassing all levels of the serotonergic
and pontine raphe complex, and the possibility that the two
messengers coexist in a subdivision(s) of this complex in DS
subjects and/or control brains cannot be excluded.
vi) The apparent absence of a molecule in histochemical stud-
ies should be interpreted with caution in general, and even
more so when human postmortem tissue is involved. There-
fore, the comparison between the results in Le Maître, et al.
(32) and the present biochemical findings is capricious. For
example, the failure to detect GALR1 transcript in locus
coeruleus neurons with in situ hybridization, despite the
high mRNA levels shown here in the locus coeruleus sam-
ple, warrants further investigation.
vii) In studies of this type it may be difficult to draw any con-
clusions about the relationship between gene expression
and DNA methylation. However, mechanistic in vitro stud-
ies are needed to delineate a causal relationship between
the two. In addition, interpretation of methylation status for
GalR1 and GalR2 should be carried out also, because meth-
ylation changes might occur at other CpG sites within the
genome that have not been studied here.
Barde et al. www.pnas.org/cgi/content/short/1617824113 3 of 12
Fig. S1. Alterations in GALR1 and GALR2 gene expression and DNA methylation in the dorsolateral prefrontal cortex of male and female DS subjects. Gene-
expression levels of GALR1 and GALR2 in the dorsolateral prefrontal cortex of male (A and E) and female (C and G) controls and DS subjects. Percent DNA
methylation levels at individual CpG sites of the GALR1 and GALR2 gene in male (B and F) and female (D and H) control and DS subjects. All data are presented
as mean ± SEM; n = 10 per group. Significant differences between DS subjects and controls are indicated: *P < 0.05. CON, controls; DS, depressed suicide.
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Fig. S2. Alterations in GAL and GALR1-3 gene expression and DNA methylation in the anterior cingulate cortex of male and female DS subjects. Gene-ex-
pression levels of GAL and GALR1-3 in the the anterior cingulate cortex of male (A, E, I, M) and female (C, G, K, O) controls and DS subjects. Percent DNA
methylation levels at individual CpG sites of the GAL and GALR1-3 genes in male (B, F, J, N) and female (D, H, L, P) control and DS subjects. All data are
presented as mean ± SEM n = 10 per group. CON, controls; DS, depressed suicide.
Barde et al. www.pnas.org/cgi/content/short/1617824113 5 of 12
Fig. S3. Alterations in GALR1 and GALR2 gene expression and DNA methylation in the dorsal raphe nucleus of male and female DS subjects. Gene-expression
levels of GALR1 and GALR2 in the dorsal raphe nucleus of male (A and E) and female (C and G) controls and DS subjects. Percent DNA methylation levels at
individual CpG sites of the GALR1 and GALR2 gene in male (B and F) and female (D and H) control and DS subjects. All data are presented as mean ± SEM, n =
10 per group. Significant differences between DS subjects and controls are indicated: *P < 0.05. CON, controls; DS, depressed suicide.
Barde et al. www.pnas.org/cgi/content/short/1617824113 6 of 12
Fig. S4. Alterations in GALR1 and GALR2 gene expression and DNA methylation in the locus coeruleus of male and female DS subjects. Gene-expression levels
of GALR1 and GALR2 in the locus coeruleus of male (A and E) and female (C and G) controls and DS subjects. Percent DNA methylation levels at individual CpG
sites of the GALR1 and GALR2 gene in male (B and F) and female (D and H) control and DS subjects. All data are presented as mean ± SEM; n = 10 per group.
CON, controls; DS, depressed suicide.
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Fig. S5. Alterations in GAL and GALR1-3 gene expression and DNA methylation in the medullary raphe nuclei of male and female DS subjects. Gene ex-
pression levels of GAL and GALR1-3 in the medullary raphe nuclei of male (A, E, I, and M) and female (C, G, K, and O) controls and DS subjects. Percent DNA
methylation levels at individual CpG sites of the GAL and GALR1-3 genes in male (B, F, J, and N) and female (D, H, L, and P) control and DS subjects. All data are
presented as mean ± SEM; n = 10 per group. Significant differences between DS subjects and controls are indicated: *P < 0.05, **P < 0.01. CON, controls; DS,
depressed suicide.
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Fig. S6. Genomic location of the regions analyzed by bisulfite pyrosequencing (A) and their respective primer sequences (B). Transcription factor binding sites
analyzed by JASPER for GAL and GALR3 (C). Analyzed regions (blue arrows): GAL: promoter region between −606 and −569 bp upstream of the transcriptional
start site (TSS); GALR1: exon 1 between 1,096 and 1,132 bp downstream of the TSS; GALR2: promoter region between −123 and −111 bp upstream of the TSS;
GALR3 gene: between 83 and 107 bp downstream of the end of the gene. Double-headed green arrows depict CpG islands.
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Fig. S7. RIA of GAL-like immunoreactivity (GAL-LI) in tissue extracts from male (A–E) and female (F–J) DS subjects and controls. The GAL concentration was
measured in the five regions studied, and a significant increase was observed in the locus coeruleus of female DS subjects compared with controls. Data are
shown as mean ± SEM. ACC, anterior cingulate cortex; DRN, dorsal raphe nucleus; LC, locus coeruleus; MRN, medullary raphe nucleus; PFC, prefrontal cortex.
*P < 0.05.
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Table S1. Clinicopathological information for DS subjects and controls
Sex Age, y Cause of death PMI pH Axis 1 Axis 1 dependence
Substance
at death
Psychiatric
medication last 3 mo
Male 63 Accident 13 6.84 Nil Nil Nil Yes
Male 81 Accident 98.7 6.80 Nil Nil AD (SSRI), AP Yes
Male 41 Natural 24 6.00 Nil Nil Nil Nil
Male 46 Natural 19.5 6.42 Nil Nil Nil Nil
Male 64 Natural 70 5.65 Nil Nil Nil N/A
Male 71 Natural 17 6.20 Nil Nil Nil Nil
Male 43 Natural 27 6.70 Nil Nil Cbd + Metab Nil
Male 51 Accident 15 6.83 Nil Nil Eth Nil
Male 55 Accident 24 6.75 Nil Nil Nil Nil
Male 40 Accident 24 6.32 Nil SD Opt, BZ N/A
Male 42 Accident 63 6.75 Nil Nil Nil Nil
Male 59 Accident 72.7 6.76 Nil Nil Nil N/A
Male 26 Accident 12 6.75 Nil Nil Eth, Cbd Nil
Male 42 Natural 20 6.62 Nil Nil BZ BZ
Male 47 Natural 12 6.49 Nil Nil Nil Nil
Male 54 Natural 25.2 6.61 Nil Nil N/A N/A
Male 52 Natural 72.5 6.11 Nil Nil Nil Nil
Male 55 Natural 27.5 5.80 Nil Nil Nil N/A
Male 48 Natural 14 6.25 Nil Nil Eth Nil
Male 57 Natural 115.3 6.34 MDD SD BZ, AD (TCA)+
Metb, Eth
N/A
Male 40 Suicide 23 6.21 MDD SD Nil N/A
Male 42 Suicide 21 6.40 MDD Nil AD (TCA) Classic AD, BZ
Male 45 Suicide 20.5 6.57 MDD SD Eth N/A
Male 68 Suicide 32 6.93 dD, NOS Nil Nil N/A
Male 67 Suicide 56 6.85 MDD Nil Nil Nil
Male 77 Suicide 26.7 6.30 dD, NOS Nil N/A Nil
Male 64 Suicide 27.7 6.25 dD, NOS Nil AD (SSRI) AD (SSRI)
Male 53 Suicide 29 6.30 dD, NOS SD Nil N/A
Male 53 Suicide 14 6.64 dD, NOS Nil N/A N/A
Male 48 Suicide 21.5 6.79 MDD SD Eth, AD (SSRI), BZ AD (SSRI)
Male 39 Suicide 90 6.74 dD, NOS Nil Eth N/A
Male 40 Suicide 20 6.33 MDD SD Eth, BZ, Coc+Metb AD (SSRI), BZ
Male 42 Suicide 64 6.78 MDD Nil Eth, DPH+Metb AD (SSRI)
Male 52 Suicide 86.5 6.20 MDD SD Eth, Coc Nil
Male 48 Suicide 15 6.78 MDD SD SD Eth, AD (SNRI)
Female 66 Accident 61 6.80 Nil Nil N/A Nil
Female 76 Accident 26.5 6.50 Nil Nil Nil N/A
Female 81 Natural 83 6.50 Nil Nil Nil BZ
Female 72 Natural 17 6.10 Nil Nil N/A Nil
Female 51 Natural 111.3 6.50 Nil Nil AD (SSRI) Classic AD
Female 68 Natural 74.3 6.21 Nil Nil Mor, AH N/A
Female 81 Natural 44.6 5.91 Nil Nil BZ, DPH Nil
Female 49 Accident 67.2 6.81 Nil Nil DPH N/A
Female 79 Accident 61.5 6.40 Nil Nil Barb, BZ Nil
Female 82 Natural 106 7.00 Nil Nil Nil N/A
Female 40 Natural 106.5 6.50 dD, NOS Nil N/A Nil
Female 76 Natural 10.4 5.79 Nil Nil N/A Nil
Female 70 Natural 37 5.7 Nil Nil N/A Nil
Female 86 Natural 23.2 5.65 Nil Nil N/A Nil
Female 75 Natural 10.7 5.68 Nil Nil N/A Nil
Female 65 Suicide 64 6.31 MDD Nil BZ, Cd AD (SSRI, SARI,
SNDRI & NaSSA), BZ
Female 49 Suicide 59.5 7.50 MDD Nil Opd, BZ, Opt AD (SSRI), BZ
Female 55 Suicide 26.2 6.50 MDD Nil Eth Antimanic
Female 75 Suicide 97 6.50 MDD Nil AD (SNRI), BZ AD (SNRI), AP
Female 85 Suicide 87 6.50 MDD Nil βB, AD (SSRI) AD (SSRI & SNRI)
Female 80 Suicide 46.9 7.00 dD, NOS Nil AD (SSRI)
and metab
AD (SSRI)
Female 59 Suicide 25.6 6.27 MDD Nil AD (NaSSA) AD (SSRI), BZ
Female 25 Suicide 20 6.73 dD, NOS Nil Nil N/A
Female 46 Suicide 15 6.53 MDD Nil Eth, Barb, BZ AD (SSRI & NaSSA), AP, BZ
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Table S1. Cont.
Sex Age, y Cause of death PMI pH Axis 1 Axis 1 dependence
Substance
at death
Psychiatric
medication last 3 mo
Female 40 Suicide 49.5 6.81 MDD Nil AC, AD (SNRI), BZ AD (TCA & SNRI), BZ, AC
Female 25 Suicide 56 6.55 MDD Nil N/A AP
Female 51 Suicide 36 6.86 MDD SD Cd, Eth, Opt AD (SSRI), BZ
Female 44 Suicide 60 6.86 MDD SD Eth Nil
Female 32 Suicide 41 6.89 MDD Nil N/A AD (SSRI), BZ
Female 41 Suicide 54.2 6.70 MDD Nil Nil N/A
Female 48 Suicide 36.7 6.50 MDD Nil BZ, AD (Non-TCA & SNRI) N/A
AC, anticonvulsant; AD, antidepressant: AH, antihistamine; AP, antipsychotic; Barb, barbiturate; βB, β-blocker; BZ, benzodiazepine; Cbd, cannabinoid; Cd,
codeine; Coc, cocaine; dD, depressive disorders; DPH, diphenhydramine; Eth, ethanol; MDD, major depressive disorder; Metab, metabolite; Mor, morphine;
NaSSA, noradrenergic and specific serotonergic antidepressant; N/A, not available; NOS, not otherwise specified; Opd, opioid; Opt, opiate; SARI, serotonin
antagonist and reuptake inhibitor; SD, substance dependence; SNDRI, serotonin-norepinephrine-dopamine reuptake inhibitor; SNRI, serotonin and noradren-
aline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
Table S2. Raw Ct values ± SEM for the samples analyzed from
male and female control and DS subjects
Region GAL GalR1 GalR2 GalR3
DLPFC 27.1 ± 0.2 25.7 ± 0.2 31.4 ± 0.2 33.2 ± 0.1
ACC 27.5 ± 0.1 28.6 ± 0 31.6 ± 0.2 33.5 ± 0.2
DRN 26.2 ± 0.4 27 ± 0.4 29.3 ± 0.2 31.5 ± 0.4
LC 24.6 ± 0.5 26.4 ± 0.6 32.3 ± 0.1 31.4 ± 0.6
MRN 25.2 ± 0.4 26.9 ± 0 34.6 ± 0.2 31.9 ± 0.4
ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; DRN,
dorsal raphe nucleus; LC, locus coeruleus; MRN, medullary raphe nucleus.
Table S3. The matrix of pairwise comparisons probabilities
shows ANOVA probability at the top and the result of Tukey’s
honestly significant difference multiple comparisons
Variable DLPFC ACC DRN LC MRN
GAL (P < 0.001)
DLPFC 1.000
ACC 0.748 1.000
DRN <0.001 0.015 1.000
LC <0.001 <0.001 <0.001 1.000
MRN <0.001 <0.001 <0.001 0.556 1.000
GalR1 (P < 0.001)
DLPFC 1.000
ACC <0.001 1.000
DRN <0.001 <0.001 1.000
LC <0.001 0.193 0.081 1.000
MRN <0.001 0.010 0.645 0.782 1.000
GalR2 (P < 0.001)
DLPFC 1.000
ACC 0.718 1.000
DRN <0.001 <0.001 1.000
LC 0.015 <0.001 <0.001 1.000
MRN <0.001 <0.001 <0.001 <0.001 1.000
GalR3 (P < 0.001)
DLPFC 1.000
ACC 0.230 1.000
DRN <0.001 <0.001 1.000
LC <0.001 <0.001 0.190 1.000
MRN <0.001 <0.001 0.154 <0.001 1.000
ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; DRN,
dorsal raphe nucleus; LC, locus coeruleus; MRN, medullary raphe nucleus.
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